Ann: Mayne Pharma announces sale of Metrics Contract Services, page-110

Mayne Pharma Group is bordering on breakeven, according to the 6 Australian Pharmaceuticals analysts. They expect the company to post a final loss in 2022, before turning a profit of AU$15m in 2023. Therefore, the company is expected to breakeven roughly 2 years from today. In order to meet this breakeven date, we calculated the rate at which the company must grow year-on-year. It turns out an average annual growth rate of 112% is expected, which is rather optimistic! If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.